The Latest Breaking News from GSK

GSK raised its outlook for the second time this year on the back of a strong launch for its RSV vaccine. But GSK stock fell.

Victorians have been warned to prepare for the possibility of thunderstorm asthma again this season.

This week, the UN convinced companies to report new nature-related disclosures.

Incyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment.

Moderna said Wednesday its flu shot outperformed broadly used vaccines from Sanofi and GSK. The results bolstered Moderna stock.

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

The Medicines and Healthcare products Regulatory Agency (MHRA) approved GSK’s jab, known as Arexvy, for use among older adults in July.

He bills himself as an iconoclast ready to shake up the Republican Party after making millions trying to do the same in the biotech industry.

There are now RSV vaccines approved for older adults and for pregnant people, and antibody shots (not vaccines) available for babies. What's the difference?